These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31471633)

  • 1. Treatment intensification strategies after initial metformin therapy in adult patients with type-2 diabetes: results of the DPV and DIVE registries.
    Hartmann B; Lanzinger S; van Mark G; Wosch FJ; Durmaz M; Plaumann M; Sziegoleit S; Seufert J; Holl RW; Bramlage P;
    Acta Diabetol; 2020 Feb; 57(2):229-236. PubMed ID: 31471633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes.
    Anyanwagu U; Mamza J; Mehta R; Donnelly R; Idris I
    Heart; 2016 Oct; 102(19):1581-7. PubMed ID: 27217068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and treatment patterns of adding a third agent to 2 OADs in patients with type 2 diabetes.
    Levin PA; Wei W; Zhou S; Xie L; Baser O
    J Manag Care Spec Pharm; 2014 May; 20(5):501-12. PubMed ID: 24761822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes.
    Preiss D; Dawed A; Welsh P; Heggie A; Jones AG; Dekker J; Koivula R; Hansen TH; Stewart C; Holman RR; Franks PW; Walker M; Pearson ER; Sattar N;
    Diabetes Obes Metab; 2017 Mar; 19(3):356-363. PubMed ID: 27862873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI; Cincotta AH; Scranton RE; Bohannon N; Ezrokhi M; Gaziano JM
    Endocr Pract; 2012; 18(6):931-43. PubMed ID: 23186965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O; Sokolovskaya V; Morozova A; Valeeva F; Zanozina O; Sazonova O; Zhadanova E; Starceva M; Kazakova E; Saifullina M; Shapiro I; Tarasov A; Al-Tayar B; Starkova N
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of treatment intensification to basal-bolus therapy in patients with type 2 diabetes on previous basal insulin-supported oral therapy with insulin glargine or supplementary insulin therapy with insulin glulisine: the PARTNER observational study.
    Pfohl M; Siegmund T; Pscherer S; Pegelow K; Seufert J
    Vasc Health Risk Manag; 2015; 11():569-78. PubMed ID: 26604774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors as add-on therapy for patients with type 2 diabetes? A systematic review and meta-analysis of surrogate metabolic endpoints.
    Patoulias D; Katsimardou A; Kalogirou MS; Zografou I; Toumpourleka M; Imprialos K; Stavropoulos K; Stergiou I; Papadopoulos C; Doumas M
    Diabetes Metab; 2020 Sep; 46(4):272-279. PubMed ID: 32437914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between changes in glucagon-like peptide-1 and bodyweight reduction in patients receiving acarbose or metformin treatment.
    Wang N; Zhang JP; Xing XY; Yang ZJ; Zhang B; Wang X; Yang WY
    J Diabetes; 2017 Aug; 9(8):728-737. PubMed ID: 27717194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective real-world study of dapagliflozin versus other oral antidiabetic drugs added to metformin in patients with type 2 diabetes.
    Huang H; Bell KF; Gani R; Tugwell CW; Eudicone JM; Krukas-Hampel MR
    Am J Manag Care; 2018 Apr; 24(8 Suppl):S132-S137. PubMed ID: 29693359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is insulin the preferred treatment for HbA1c >9%?
    Bloomgarden Z
    J Diabetes; 2017 Sep; 9(9):814-816. PubMed ID: 28589542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment intensification using long-acting insulin -predictors of future basal insulin supported oral therapy in the DIVE registry.
    Danne T; Bluhmki T; Seufert J; Kaltheuner M; Rathmann W; Beyersmann J; Bramlage P;
    BMC Endocr Disord; 2015 Oct; 15():54. PubMed ID: 26446863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy with mealtime human insulin therapy in secondary OAD failure.
    Altuntas Y; Ozen B; Ozturk B; Sengul A; Ucak S; Ersoy O; Karul S
    Diabetes Obes Metab; 2003 Nov; 5(6):371-8. PubMed ID: 14617222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis.
    Liu SC; Tu YK; Chien MN; Chien KL
    Diabetes Obes Metab; 2012 Sep; 14(9):810-20. PubMed ID: 22486990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow-Up Registry.
    Jung H; Tittel SR; Schloot NC; Heitmann E; Otto T; Lebrec J; Pavel M; Lanzinger S
    Diabetes Obes Metab; 2023 Jul; 25(7):1813-1822. PubMed ID: 36855221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.